CONTENTS:
- Trends in substance use and related harms among older adults in high-income countries [Editorial]. Sutherland R., Gisev N., Larney S., p. 1676-1678.
- Expanding and adapting prevention and treatment options for older adults who engage in harmful use of substances [Editorial]. Kuerbis A., p. 1679-1681.
- Will Australia's tightened prescription system reduce nicotine vaping among young people? [Addiction opinion and debate]. Hall W.D., p. 1682-1688.
- Addictive and harmful vapes must never be sold as a consumer good. Freeman B., Watts C., p. 1689-1690.
- The ends do not justify the means when it comes to Australia's vaping policy. Cox S., p. 1691-1692.
- Will Australia's tightened prescription system reduce nicotine vaping among young people? Gravely S., Fong G.T., p. 1693-1695.
- Towards more practicable e-cigarette regulation in Australia. Hall W., p. 1696-1697.
- Electronic cigarettes and subsequent use of cigarettes in young people: An evidence and gap map. Conde M., Tudor K., Begh R., Nolan R., Zhu S., Kale D., et al., p. 1698-1708.
- Commentary on Conde et al.: Evidence and gap map offer an important opportunity for dialogue and refinement of the gateway hypothesis controversy. Selya A., Gitchell J.G., p. 1709-1710.
- Commentary on Conde et al.: Addressing evidence gaps on the impact of vaping among young people. East K., p. 1711-1712.
- Systematic review and meta-analyses of cytisine to support tobacco cessation. Puljevic C., Stjepanovic D., Meciar I., Kang H., Chan G., Morphett K., et al., p. 1713-1725.
- Expanding our understanding of long-term trends in alcohol abstention and consumption in England (2001-19) using two age-period-cohort approaches. Opazo Breton M., Henney M., Kersbergen I., Brennan A., Holmes J., p. 1726-1736.
- The association of smoking with different eating and dietary behaviours: A cross-sectional analysis of 80?296 United Kingdom adults. Alruwaili A., King J.A., Deighton K., Kelly B.M., Liao Z., Innes A., et al., p. 1737-1750.
- Prospective longitudinal relations among frequent social media use, nicotine vaping and experiencing internalizing mental health problems. Lee S., Elam K., Lohrmann D., Luo J., Chow A., Seo D.C., p. 1751-1761.
- Effectiveness of residential versus outpatient therapy for smoking cessation: The START randomized clinical trial. Dickreuter J.L., Schmoor C., Jähne A., Bengel J., Pschichholz B., Lorz C., et al., p. 1762-1773.
- Young adult retail purchases of cannabis, product category preferences and sales trends in California 2018-21: Differences compared with older adults. Pechmann C., Calder D., Timberlake D., Rhee J., Padon A., Silver L., p. 1774-1783.
- Changes in prenatal cannabis-related diagnosed disorders after the Cannabis Act and the COVID-19 pandemic in Quebec, Canada. Nazif-Munoz J.I., Martinez P., Huynh C., Massamba V., Zefania I., Rochette L., et al., p. 1784-1791.
- Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning. Nateghi Haredasht F., Fouladvand S., Tate S., Chan M.M., Yeow J.J.L., Griffiths K., et al., p. 1792-1802.
- Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder. Mojtabai R., Susukida R., Farokhnia M., Nguyen T.Q., Dunn K.E., Amin-Esmaeili M., p. 1803-1812.
- Predictors of alcohol and other drug treatment completion among young people accessing residential and community-based treatment: A retrospective analysis of routinely collected service data. Wells M., Kelly P.J., Mullaney L., Lee M.L., Stirling R., Etter S., et al., p. 1813-1825.
- The relationship between gambling behaviour and gambling-related harm: A data fusion approach using open banking data. Zendle D., Newall P., p. 1826-1835.
- Commentary on Zendle and Newall: The need for direct evaluation of the UK's gambling affordability checks policy. Heirene R.M., p. 1836-1837.
- Better data access can lead to better collaborative conclusions: Results of a discussion with Heirene. Zendle D., Newall P., p. 1838-1839.
- Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Li M.J., Chau B., Belin T., Carmody T., Jha M.K., Marino E.N., et al., p. 1840-1845.